Regenxbio (STU:RB0) Cyclically Adjusted Revenue per Share: €3.21 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:RB0 Regenxbio Inc STU:RB0
55 GF Score
Price €8.90
GF Value €13.34
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Regenxbio Cyclically Adjusted Revenue per Share?

Regenxbio STU:RB0 -1.90% 55 Cyclically Adjusted Revenue per Share is €3.21 as of Mar. 2026. GuruFocus rates STU:RB0 with a GF Score™ of 55/100 and a GF Value™ of €13.34 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Regenxbio's adjusted revenue per share for the three months ended in Mar. 2026 was €0.105. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.21 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Regenxbio's average Cyclically Adjusted Revenue Growth Rate was 6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-23), Regenxbio's current stock price is €8.904. Regenxbio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €3.21. Regenxbio's Cyclically Adjusted PS Ratio of today is 2.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Regenxbio was 5.92. The lowest was 1.53. And the median was 2.76.


Regenxbio  (STU:RB0) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Regenxbio's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8.904/3.21
=2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Regenxbio was 5.92. The lowest was 1.53. And the median was 2.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Regenxbio Cyclically Adjusted Revenue per Share Related Terms


Regenxbio Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Regenxbio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenxbio Cyclically Adjusted Revenue per Share Chart

Regenxbio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.00 3.05

Regenxbio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.25 3.01 3.12 3.05 3.21

STU:RB0 vs ALT, ASMB, CTNM: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Regenxbio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regenxbio's Cyclically Adjusted PS Ratio falls into.


STU:RB0
55GF Score
Regenxbio Inc STU:RB0
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regenxbio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regenxbio's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.105/330.2130*330.2130
=0.105

Current CPI (Mar. 2026) = 330.2130.

Regenxbio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.080 241.018 0.110
201609 0.004 241.428 0.005
201612 0.061 241.432 0.083
201703 0.016 243.801 0.022
201706 0.190 244.955 0.256
201709 0.036 246.819 0.048
201712 0.055 246.524 0.074
201803 3.133 249.554 4.146
201806 0.972 251.989 1.274
201809 0.134 252.439 0.175
201812 0.920 251.233 1.209
201903 0.022 254.202 0.029
201906 0.190 256.143 0.245
201909 0.363 256.759 0.467
201912 0.287 256.974 0.369
202003 0.430 258.115 0.550
202006 0.395 257.797 0.506
202009 2.160 260.280 2.740
202012 0.471 260.474 0.597
202103 0.379 264.877 0.472
202106 0.430 271.696 0.523
202109 0.614 274.310 0.739
202112 7.248 278.802 8.585
202203 0.470 287.504 0.540
202206 0.716 296.311 0.798
202209 0.619 296.808 0.689
202212 0.683 296.797 0.760
202303 0.411 301.836 0.450
202306 0.424 305.109 0.459
202309 0.616 307.789 0.661
202312 0.463 306.746 0.498
202403 0.314 312.332 0.332
202406 0.409 314.175 0.430
202409 0.429 315.301 0.449
202412 0.398 315.605 0.416
202503 1.601 319.799 1.653
202506 0.360 322.561 0.369
202509 0.490 324.800 0.498
202512 0.501 324.054 0.511
202603 0.105 330.213 0.105

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €3.21 mean?
Regenxbio (STU:RB0) has a Cyclically Adjusted Revenue per Share of €3.21 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Regenxbio and its competitors.
Is Regenxbio's Cyclically Adjusted Revenue per Share too high?
Regenxbio's current Cyclically Adjusted Revenue per Share is €3.21. Overall, Regenxbio has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Regenxbio's Cyclically Adjusted Revenue per Share compare to ALT and ASMB?
Regenxbio's Cyclically Adjusted Revenue per Share of €3.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Regenxbio and its competitors. Regenxbio's current Cyclically Adjusted Revenue per Share is €3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenxbio stock overvalued right now?
Based on GuruFocus' analysis, Regenxbio (STU:RB0) is currently considered Possible Value Trap. The stock's GF Value™ is €13.34, compared to a current price of €8.90 — trading 33.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €3.21. Regenxbio's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Regenxbio (STU:RB0), the current Cyclically Adjusted Revenue per Share is €3.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regenxbio (STU:RB0) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of €8.90 is trading 33.3% below its estimated GF Value™ of €13.34. GuruFocus considers Regenxbio to be Possible Value Trap.

Key valuation signals for STU:RB0:

  • Cyclically Adjusted Revenue per Share: €3.21
  • GF Value™: €13.34 vs. price of €8.90 (33.3% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the STU:RB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regenxbio Business Description

Other Exchanges RGNX:USA
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
55GF Score

Get the complete analysis for STU:RB0

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.90
Price
€13.34
GF Value